hematoxylin has been researched along with apigenin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arora, S; Chaturvedi, A; Heuser, M; Joshi, G; Kumar, R; Patil, S | 1 |
| Dong, H; Huang, N; Jin, Z; Kang, J; Ning, B; Pan, L; Tian, L; Zhang, X; Zhang, Y | 1 |
2 other study(ies) available for hematoxylin and apigenin
| Article | Year |
|---|---|
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
Topics: Allosteric Regulation; Allosteric Site; Carrier Proteins; Chemistry, Pharmaceutical; Glycolysis; Humans; Membrane Proteins; Protein Kinase Inhibitors; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2022 |
Apigenin inhibits fibrous scar formation after acute spinal cord injury through TGFβ/SMADs signaling pathway.
Topics: Actins; Animals; Apigenin; Cicatrix; Collagen; Eosine Yellowish-(YS); Fibronectins; Hematoxylin; Mice; Nerve Growth Factors; Recovery of Function; Signal Transduction; Spinal Cord; Spinal Cord Injuries; Transforming Growth Factor beta | 2022 |